---
title: "Zentalis Pharmaceuticals, Inc. (ZNTL.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ZNTL.US.md"
symbol: "ZNTL.US"
name: "Zentalis Pharmaceuticals, Inc."
industry: "生物技术"
---

# Zentalis Pharmaceuticals, Inc. (ZNTL.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [zentalis.com](https://zentalis.com) |

## Company Profile

Zentalis Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于发现和开发小分子治疗药物，以治疗美国的各种癌症。该公司正在开发 azenosertib，目前正在进行针对卵巢癌和其他肿瘤类型的三期临床试验。它还开发了 ZN-c3-001，这是一个评估 azenosertib 单药治疗实体肿瘤的一期研究；MAMMOTH（ZN-c3-006）是一个针对 PARP 抑制剂耐药卵巢癌患者的 azenosertib 的一期/二期临床试验。该公司与 Recurium IP Holdings, LLC 签订了许可协议和战略合作

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: D (0.72)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 266 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -33.76% |  |
| Net Profit YoY | 16.72% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.65 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 163.17M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 26.86M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -49.18% | E |
| Profit Margin | -555.80% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -33.76% | E |
| Net Profit YoY | 16.72% | B |
| Total Assets YoY | -27.38% | E |
| Net Assets YoY | -28.63% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -17.99% | D |
| OCF YoY | -33.76% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.07 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 22.73% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Zentalis Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-49.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-555.80%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-33.76%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "16.72%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-27.38%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-28.63%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-17.99%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-33.76%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.07",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "22.73%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.09 | 195/604 | - | - | - |
| PB | 0.65 | 51/604 | 0.44 | 0.38 | 0.32 |
| PS (TTM) | 6.07 | 113/604 | 4.40 | 3.76 | 3.24 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 44% |
| Overweight | 0 | 0% |
| Hold | 5 | 56% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.42 |
| Highest Target | 10.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ZNTL.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ZNTL.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ZNTL.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.